183 related articles for article (PubMed ID: 23396375)
1. Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Zhuang ZX; Zhu H; Wang J; Zhu MG; Wang H; Pu WY; Bian HH; Chen L; Zhang H
Acta Pharmacol Sin; 2013 Apr; 34(4):570-80. PubMed ID: 23396375
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and bioequivalence study of new S-1 capsule in Chinese cancer patients.
Chen Y; Jiang Y; Qu J; Wang Q; Bai Y; Shi J; Shi Y; Chen X; Yang N; Heng J; Li K
Eur J Pharm Sci; 2020 Aug; 151():105384. PubMed ID: 32470574
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients.
Lee HW; Seong SJ; Kang WY; Ohk B; Gwon MR; Kim BK; Cho S; Cho K; Sung YK; Yoon YR; Kim JG
Drug Des Devel Ther; 2019; 13():3127-3136. PubMed ID: 31564829
[TBL] [Abstract][Full Text] [Related]
4. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
6. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
9. Comparative fasting bioavailability of 2 bepotastine formulations in healthy male Chinese volunteers: an open-label, randomized, single-dose, 2-way crossover study.
Shentu J; Zhou H; Hu X; Wu G; Wu L; Zhu M; Zhai Y; Zheng Y; Liu J
Clin Ther; 2014 Apr; 36(4):579-85. PubMed ID: 24656153
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
12. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
13. [Phase I study of S-1. S-1 Study Group].
Taguchi T; Inuyama Y; Kanamaru R; Hasegawa K; Akazawa S; Niitani H; Furue H; Kurihara M; Ota K; Suga S; Ariyoshi Y; Takai S; Shimoyama T; Toge T; Takashima S; Sugimachi K; Hara Y; Fujita H; Kimura K; Saito T; Tsukagoshi S; Nakao I
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2253-64. PubMed ID: 9422070
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence Study of Palbociclib Capsules in Healthy Chinese Subjects Under Fasting and Fed Conditions.
Chu NN; Zhang L; Wang J; Gu X; Ding Y; Huang K; Que LL; He Q
Clin Drug Investig; 2022 Jan; 42(1):53-63. PubMed ID: 34837169
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
16. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Liu YM; Pu HH; Liu GY; Jia JY; Weng LP; Xu RJ; Li GX; Wang W; Zhang MQ; Lu C; Yu C
Clin Ther; 2010 Jul; 32(7):1396-407. PubMed ID: 20678686
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers.
Jia JY; Zhang MQ; Liu YM; Liu Y; Liu GY; Li SJ; Lu C; Weng LP; Qi YL; Yu C
Clin Ther; 2010 Jul; 32(7):1387-95. PubMed ID: 20678685
[TBL] [Abstract][Full Text] [Related]
20. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
